{"preliminary_commentary":{"by_channel":{"x_thread":14,"podcast":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05585554\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"LAP-ABLATE","nct_id":"NCT05585554","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lap-ablate-nct05585554. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LAP-ABLATE","arms":[{"description":"Induction Chemotherapy + MRIdian SMART 50 Gy in 5 fractions","label":"Ablative MRIdian SMART","type":"EXPERIMENTAL"},{"description":"Induction chemotherapy alone","label":"No ablative MRIdian SMART","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Pancreatic Cancer"],"enrollment":{"count":267,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"MRIdian","otherNames":[],"type":"RADIATION"}],"last_update":"2022-10-19","lead_sponsor":"Viewray Inc.","official_title":"Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy (LAP-ABLATE)","overall_status":"NOT_YET_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2028-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"2-years"}],"references":[{"citation":"Rudra S, Jiang N, Rosenberg SA, Olsen JR, Roach MC, Wan L, Portelance L, Mellon EA, Bruynzeel A, Lagerwaard F, Bassetti MF, Parikh PJ, Lee PP. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019 May;8(5):2123-2132. doi: 10.1002/cam4.2100. Epub 2019 Apr 1.","pmid":"30932367","type":"BACKGROUND"},{"citation":"Eaton AA, Karanicolas P, Johnson MChir CD, Bottomley A, Allen PJ, Gonen M. Psychometric Validation of the EORTC QLQ-PAN26 Pancreatic Cancer Module for Assessing Health Related Quality of Life after Pancreatic Resection. JOP. J Pancreas (Online) 2017; 18(1):19-25.","pmid":null,"type":"BACKGROUND"}],"start_date":{"date":"2023-07","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy","url":"https://clinicaltrials.gov/study/NCT05585554"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lap-ablate-nct05585554"}